TrialPath

1 study

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Obesity / overweight

    📍 University of New Mexico Health Sciences Center · Albuquerque, NM · Get directions →

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity.

    ✓ Study care freeEarly Phase 1Ages 18–75Learn more →